MPLT (MapLight Therapeutics) EBIT: $-210.04 Mil (TTM As of Mar. 2026)


MPLT MapLight Therapeutics Inc MPLT
14 GF Score
Price $37.11
! 4 Warning Signs
View Full Analysis

What is MapLight Therapeutics EBIT?

MapLight Therapeutics MPLT +3.09% 14 EBIT is $-210.04 Mil as of Mar. 2026. GuruFocus rates MPLT with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

MapLight Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-64.50 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-210.04 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MapLight Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -196.39%. MapLight Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2,481.96%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. MapLight Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -15.24%.

MapLight Therapeutics  (NAS:MPLT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MapLight Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-258.012 * ( 1 - 0% )/( (165.233 + 97.524)/ 2 )
=-258.012/131.3785
=-196.39 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=479.512 - 9.176 - ( 305.103 - max(0, 16.229 - 324.67+305.103))
=165.233

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=418.788 - 11.151 - ( 310.113 - max(0, 14.283 - 327.228+310.113))
=97.524

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

MapLight Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-258.012/( ( (6.583 + max(4.229, 0)) + (6.227 + max(3.752, 0)) )/ 2 )
=-258.012/( ( 10.812 + 9.979 )/ 2 )
=-258.012/10.3955
=-2,481.96 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 19.567) - (9.176 + 0 + 6.162)
=4.229

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 17.115) - (11.151 + 0 + 2.212)
=3.752

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

MapLight Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-210.041/1378.256
=-15.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MapLight Therapeutics EBIT Related Terms

MapLight Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for MapLight Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MapLight Therapeutics EBIT Chart

MapLight Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBIT
-31.25 -57.28 -82.95 -169.08

MapLight Therapeutics Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.54 -30.66 -31.50 -83.38 -64.50

MPLT vs COAG, CAPR, NVAX: EBIT Comparison

For the Biotechnology subindustry, MapLight Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MapLight Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MapLight Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MapLight Therapeutics's EV-to-EBIT falls into.


MPLT
14GF Score
MapLight Therapeutics Inc MPLT
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MapLight Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-210.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-210.04 Mil mean?
MapLight Therapeutics (MPLT) has a EBIT of $-210.04 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MapLight Therapeutics.
Is MapLight Therapeutics' EBIT too high?
MapLight Therapeutics' current EBIT is $-210.04 Mil. Overall, MapLight Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MapLight Therapeutics' EBIT compare to COAG and CAPR?
MapLight Therapeutics' EBIT of $-210.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MapLight Therapeutics. MapLight Therapeutics's current EBIT is $-210.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MapLight Therapeutics stock overvalued right now?
MapLight Therapeutics (MPLT) has a current EBIT of $-210.04 Mil. The current EBIT is $-210.04 Mil. MapLight Therapeutics' overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For MapLight Therapeutics (MPLT), the current EBIT is $-210.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MapLight Therapeutics Business Description

Address 800 Chesapeake Drive, Redwood City, CA, USA, 94063
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
14GF Score

Get the complete analysis for MPLT

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.11
Price